<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241384</url>
  </required_header>
  <id_info>
    <org_study_id>04-8-10</org_study_id>
    <nct_id>NCT00241384</nct_id>
  </id_info>
  <brief_title>Low Dose Supplemental External Radiation With Pd-103 Versus Pd-103 Alone for Prostate Cancer</brief_title>
  <official_title>Low Dose Supplemental External Radiation With PD-103 Versus PD-103 Alone For Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schiffler Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Theragenics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Schiffler Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate two treatment regimens for prostate cancer,
      prostate implant with 20 Gy of external beam radiation therapy versus prostate implant with 0
      Gy of external beam radiation therapy. Patients diagnosed with intermediate risk prostate
      cancer between the ages of 40 and 80 who have chosen brachytherapy with or without external
      beam radiation therapy as their intended treatment will be eligible and will be offered
      participation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 250,000 men are currently diagnosed with prostatic cancer in the United States
      each year. Of those, 70% have stage T1 or T2 disease (apparently limited to the prostate
      gland). Clinically localized prostate cancer is a spectrum of disease, ranging from good
      prognosis to poor prognosis. Patients with a PSA above 10 ng/ml or Gleason score of 7 to 10
      are referred to as intermediate risk, with approximately an 80% chance of cure.

      Implantation of radioactive sources directly into the prostate (brachytherapy) delivers a
      high, localized radiation dose while sparing most the of the bladder and rectum.
      Brachytherapy is well established for other tumor sites, and has become a standard treatment
      for prostate cancer.

      Establishing that a good quality implant alone is as effective as implant plus beam radiation
      will allow us to routinely drop the use of beam radiation, a change in policy that will
      decrease the risk of some complications, will be more convenient for patients, and will lower
      treatment costs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serial PSA : 6, 12, 18 and 24 months and then yearly.</measure>
    <time_frame>6, 12, 18 and 24 months and then yearly</time_frame>
    <description>Serial PSA : 6, 12, 18 and 24 months and then yearly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post treatment biopsies in those with persistently elevated</measure>
    <time_frame>as needed</time_frame>
    <description>Post treatment biopsies in those with persistently elevated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PSA which is suggestive of residual tumor.</measure>
    <time_frame>as needed</time_frame>
    <description>PSA which is suggestive of residual tumor.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">396</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Pd-103 with 20Gy External Beam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pd-103 with 20Gy External Beam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pd-103 alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pd-103 alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>External beam radiation</intervention_name>
    <arm_group_label>Pd-103 with 20Gy External Beam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pd-103</intervention_name>
    <arm_group_label>Pd-103 alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with previously untreated prostatic cancer.

          -  Must have PSA 10-20 ng/ml, Gleason 7 to 9

        Exclusion Criteria:

          -  Patients with proven regional lymph node involvement will be excluded.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory S Merrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schiffler Cancer Center, Wheeling, WV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kent E Wallner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Washington VA Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Administration Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108-1597</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiffler Cancer Center</name>
      <address>
        <city>Wheeling</city>
        <state>West Virginia</state>
        <zip>26003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bartolini R, Dattoli G, Giannessi L, Mezi L, Renieri A, Migliorati M, Bruni C, Couprie ME, Garzella D, Orlandi G. Saturation and electron-beam lifetime in a storage ring free-electron laser. Phys Rev E Stat Nonlin Soft Matter Phys. 2004 Mar;69(3 Pt 2):036501. Epub 2004 Mar 4.</citation>
    <PMID>15089421</PMID>
  </reference>
  <reference>
    <citation>Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):839-50.</citation>
    <PMID>10705004</PMID>
  </reference>
  <reference>
    <citation>Critz FA, Williams WH, Levinson AK, Benton JB, Holladay CT, Schnell FJ Jr. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol. 2000 Sep;164(3 Pt 1):738-41; discussion 741-3.</citation>
    <PMID>10953137</PMID>
  </reference>
  <reference>
    <citation>Merrick GS, Butler WM, Galbreath RW, Lief JH. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):41-8.</citation>
    <PMID>11516849</PMID>
  </reference>
  <reference>
    <citation>Blue E. Letting go of Ben. Nurs Spectr (Wash D C). 1999 Mar 8;9(5):20.</citation>
    <PMID>10562177</PMID>
  </reference>
  <reference>
    <citation>Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):605-14.</citation>
    <PMID>11395226</PMID>
  </reference>
  <reference>
    <citation>Blasko JC, Ragde H, Schumacher D. Transperineal percutaneous iodine-125 implantatio for prostatic carcinoma using transrectal ultrasound and template guidance. Endo/Hypertherm 1987;3:131-39.</citation>
  </reference>
  <reference>
    <citation>Wallner K, Merrick G, Butler W, Sheretz T, Sutlief S, Cavanagh W, et al. 20 Gy versus 44 Gy supplemental beam radiation combined with Pd-103 prostate brachytherapy: early results from a prospective randomized multicenter trial (submitted)2004.</citation>
  </reference>
  <reference>
    <citation>Prestidge BR, Hoak DC, Grimm PD, Ragde H, Cavanagh W, Blasko JC. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):31-9.</citation>
    <PMID>9054874</PMID>
  </reference>
  <reference>
    <citation>Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA, Shipley WU. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 1996 Aug;40(2):159-62.</citation>
    <PMID>8884970</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2005</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Schiffler Cancer Center</investigator_affiliation>
    <investigator_full_name>Gregory Merrick, M.D.</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>Prostatic Cancer</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>Prostatic neoplasm</keyword>
  <keyword>Radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

